<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) is a complex and lethal clinical syndrome accounting for an increasing number of Australian hospital separations and more than 2700 Australian <z:hpo ids='HP_0011420'>deaths</z:hpo> in 2008 </plain></SENT>
<SENT sid="1" pm="."><plain>In 2006, the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand published Guidelines for the prevention, detection and management of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> in Australia, 2006 </plain></SENT>
<SENT sid="2" pm="."><plain>Results from recently published clinical trials provide additional information to be considered in the prevention, detection and management of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In some cases, this new evidence strengthens recommendations previously made in the 2006 guidelines; in others, it provides new approaches to current recommended practice </plain></SENT>
<SENT sid="4" pm="."><plain>Areas in which there have been significant new developments include: Use of B-type natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (BNP) or N-terminal proBNP plasma level measurement in guiding treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>; New pharmacological approaches to the treatment of systolic <z:hpo ids='HP_0001635'>heart failure</z:hpo>; Drugs to avoid or use with caution in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>; Treatment of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>; Multidisciplinary care and post-discharge management programs </plain></SENT>
<SENT sid="5" pm="."><plain>While patient circumstances and clinical judgement should guide the interpretation of these findings in the clinical context, this update, together with the 2006 guidelines, provides current clinical guidance on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
</text></document>